# Saccharomyces cerevisiae CBC 1234

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/saccharomyces-cerevisiae-cbc-1234
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-03-25
**Evidence Score:** 2 / 10
**Category:** Fermented/Probiotic
**Also Known As:** Saccharomyces cerevisiae CBC 1234, S. cerevisiae CBC 1234, Baker's yeast CBC 1234, Brewer's yeast CBC 1234, CBC 1234 yeast strain, Saccharomyces cerevisiae strain CBC 1234

## Overview

Saccharomyces cerevisiae CBC 1234 is a proprietary yeast strain in the Saccharomyces cerevisiae species, which produces [beta-glucan](/ingredients/condition/immune-support)s and mannan-oligosaccharides that interact with intestinal immune receptors. As a [probiotic](/ingredients/condition/gut-health) yeast, it works by modulating gut-associated lymphoid tissue and competing with pathogenic organisms for intestinal adhesion sites.

## Health Benefits

• No specific clinical benefits documented for CBC 1234 strain - evidence limited to general S. cerevisiae strains
• Related S. boulardii strains show reduction in acute infectious diarrhea duration by ~1 day (moderate evidence from RCTs)
• Prevention of antibiotic-associated diarrhea when taken prophylactically (moderate evidence from comparable strains)
• Adjunct therapy for C. difficile colitis alongside vancomycin/metronidazole (preliminary evidence)
• In vitro studies demonstrate epithelial barrier enhancement via increased transepithelial electrical resistance (preliminary evidence)

## Mechanism of Action

Saccharomyces cerevisiae strains produce cell-wall beta-1,3/1,6-glucans and mannan-oligosaccharides that bind Dectin-1 and TLR2 receptors on intestinal dendritic cells and macrophages, triggering innate immune signaling via [NF-kB](/ingredients/condition/inflammation) and MAPK pathways. These interactions stimulate secretory IgA production and promote regulatory [T-cell](/ingredients/condition/immune-support) activity, reinforcing mucosal barrier integrity. The yeast also secretes proteases that degrade virulence factors from pathogens such as Clostridioides difficile toxins A and B, reducing their epithelial adhesion capacity.

## Clinical Summary

No strain-specific randomized controlled trials have been published for Saccharomyces cerevisiae CBC 1234 as of this writing, making direct efficacy claims unsupported by clinical evidence. Extrapolation from closely related S. boulardii (CNCM I-745) RCTs — including a 2010 Cochrane review of 21 trials with over 4,500 participants — shows reduction of acute infectious diarrhea duration by approximately one day. A separate meta-analysis of 11 RCTs found S. boulardii reduced antibiotic-associated diarrhea risk by roughly 53% (RR 0.47, 95% CI 0.35–0.63). Until CBC 1234-specific trials are conducted, these outcomes cannot be confidently attributed to this strain, as [probiotic](/ingredients/condition/gut-health) effects are highly strain-dependent.

## Nutritional Profile

Saccharomyces cerevisiae CBC 1234, as a yeast-based probiotic ingredient, carries the general compositional profile of S. cerevisiae cells, though exact strain-specific concentrations for CBC 1234 are not independently documented in public literature. Based on established S. cerevisiae compositional data: Protein: 40–50% of dry cell weight, comprising all essential amino acids with notably high glutamic acid, aspartic acid, and leucine content; bioavailability is moderate as intact cell walls (beta-glucan/mannan matrix) limit direct protein absorption unless cell walls are disrupted. Carbohydrates: 30–40% dry weight, primarily as beta-1,3/1,6-glucans (comprising ~30–60% of cell wall mass) and mannan-oligosaccharides (MOS); these are not absorbed but act as [prebiotic](/ingredients/condition/gut-health)-like substrates and [immunomodulatory](/ingredients/condition/immune-support) compounds. Fat: 2–6% dry weight, predominantly unsaturated fatty acids (oleic acid C18:1, palmitoleic acid C16:1). B-Vitamins: naturally rich in B-complex — thiamine (B1) ~1–5 mg/100g dry weight, riboflavin (B2) ~3–5 mg/100g, niacin (B3) ~30–50 mg/100g, pantothenic acid (B5) ~10–20 mg/100g, pyridoxine (B6) ~3–5 mg/100g, folate (B9) ~1–3 mg/100g; B12 is absent unless fortified. Minerals: chromium (as biologically active glucose tolerance factor, GTF-chromium, ~200–400 mcg/100g), selenium (strain/growth medium dependent, typically 0.1–0.3 mg/100g in standard strains), zinc (~3–8 mg/100g), iron (~2–5 mg/100g), phosphorus (~1–2 g/100g), potassium (~1.5–2 g/100g), magnesium (~200–400 mg/100g). Bioactive compounds: beta-glucans serve as key immunomodulatory agents (TLR2/Dectin-1 agonists); MOS may competitively inhibit pathogen adhesion to intestinal epithelium. Trehalose (stress-protective disaccharide) present at ~15–20% dry weight in some preparations. Ergosterol (vitamin D2 precursor) present at ~0.3–1% dry weight; conversion to vitamin D2 requires UV exposure, which is processing-dependent. Bioavailability note: As a whole-cell probiotic preparation, most intracellular nutrients have limited bioavailability unless the product undergoes autolysis or cell wall disruption processing; CBC 1234-specific processing method not publicly documented, which materially affects nutrient release and absorption.

## Dosage & Preparation

No dosages studied for CBC 1234 specifically. Comparable S. cerevisiae/boulardii strains use: 250 mg (≥2.5 × 10^9 CFU) 1-3x daily for acute diarrhea; 50-200 mg 3x daily for prophylaxis; 100 mg 3x daily for 14 days then 50 mg for acne. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

Saccharomyces cerevisiae strains are generally recognized as safe (GRAS) by the FDA and are well tolerated in healthy adults, with the most commonly reported side effects being mild bloating and flatulence during the initial days of supplementation. Individuals with immunocompromising conditions — including HIV/AIDS, organ transplant recipients, or those on systemic corticosteroids — face a rare but documented risk of fungemia (yeast infection in the bloodstream) and should avoid live yeast supplements without physician oversight. Saccharomyces supplements may interact with antifungal medications such as fluconazole, itraconazole, and amphotericin B, which can reduce or eliminate [probiotic](/ingredients/condition/gut-health) viability. Safety data in pregnancy and lactation for CBC 1234 specifically is absent; pregnant individuals should consult a healthcare provider before use.

## Scientific Research

No human clinical trials, RCTs, or meta-analyses specifically reference Saccharomyces cerevisiae CBC 1234. Evidence is limited to general S. cerevisiae strains or S. boulardii comparators (PMID: 18416847 for strain comparison), with related strains showing efficacy in diarrhea management but no specific data for this proprietary variant.

## Historical & Cultural Context

No historical traditional medicine use documented for S. cerevisiae CBC 1234 in Ayurveda, TCM, or other systems. Modern [probiotic](/ingredients/condition/gut-health) application stems from its origins in food and brewery fermentation, with related S. boulardii strains used clinically since the 1950s.

## Synergistic Combinations

Lactobacillus acidophilus, Bifidobacterium longum, [Prebiotic](/ingredients/condition/gut-health) fibers, Zinc, Vitamin D3

## Frequently Asked Questions

### What makes Saccharomyces cerevisiae CBC 1234 different from S. boulardii?

Saccharomyces cerevisiae CBC 1234 is a distinct proprietary strain of S. cerevisiae, whereas S. boulardii (e.g., CNCM I-745) is a sub-species with its own unique genetic profile and an established body of clinical trial data. Probiotic benefits are strain-specific, meaning CBC 1234 cannot be assumed to replicate S. boulardii's documented effects on diarrhea duration or antibiotic-associated diarrhea without its own RCTs. Currently, no published strain-specific clinical data exists for CBC 1234.

### Can Saccharomyces cerevisiae CBC 1234 be taken with antibiotics?

Because CBC 1234 is a yeast rather than a bacterium, it is not killed by most common antibacterial antibiotics, which is a practical advantage over bacterial probiotics during antibiotic courses. Related S. cerevisiae and S. boulardii strains have been specifically studied for reducing antibiotic-associated diarrhea when co-administered with antibiotics. However, antifungal drugs such as fluconazole or itraconazole will destroy the yeast cells, rendering co-administration ineffective.

### What is the recommended dosage for Saccharomyces cerevisiae CBC 1234?

No strain-specific dosing guidelines have been established for CBC 1234 in published clinical literature. Dosing for comparable S. boulardii strains in clinical trials typically ranges from 250 mg to 1,000 mg per day (approximately 5–40 billion CFU/day), often split into two doses. Consumers should follow the manufacturer's label instructions and consult a healthcare provider, as optimal dosing for CBC 1234 has not been independently validated.

### Is Saccharomyces cerevisiae CBC 1234 safe for immunocompromised individuals?

Live Saccharomyces cerevisiae supplementation carries a documented, though rare, risk of fungemia in immunocompromised individuals, including those with HIV/AIDS, cancer patients on chemotherapy, and organ transplant recipients on immunosuppressants. Case reports in medical literature have linked live S. cerevisiae and S. boulardii ingestion to systemic yeast infections in these populations. Immunocompromised individuals should avoid CBC 1234 or any live yeast supplement unless explicitly cleared by a physician.

### Does Saccharomyces cerevisiae CBC 1234 contain gluten or allergens?

Saccharomyces cerevisiae is naturally derived from yeast and does not contain gluten proteins (gliadin or glutenin), making it generally suitable for individuals with celiac disease or gluten sensitivity in its purified supplement form. However, CBC 1234 is grown on fermentation media that may include grain-derived substrates, so individuals with severe allergies should verify manufacturing practices and look for third-party allergen certifications on the product label. Those with known yeast allergies should avoid this supplement entirely, as S. cerevisiae proteins can trigger hypersensitivity reactions.

### What does the clinical evidence show for Saccharomyces cerevisiae CBC 1234 specifically?

Clinical evidence specific to the CBC 1234 strain is limited, with most research conducted on related S. cerevisiae and S. boulardii strains rather than this particular isolate. Related S. cerevisiae strains have demonstrated moderate evidence for reducing acute infectious diarrhea duration by approximately one day and preventing antibiotic-associated diarrhea when taken prophylactically. The CBC 1234 strain may share similar mechanisms with these studied strains, but direct clinical trials on this exact strain are needed to confirm efficacy.

### Is Saccharomyces cerevisiae CBC 1234 effective for preventing antibiotic-associated diarrhea?

Yes, when taken prophylactically during antibiotic therapy, S. cerevisiae CBC 1234 may help prevent antibiotic-associated diarrhea based on moderate evidence from comparable S. cerevisiae strains. For optimal benefit, it should be initiated at the beginning of antibiotic treatment and continued through the full course of antibiotics plus a few days after completion. However, it should be taken at least 2–3 hours apart from antibiotics to minimize potential interactions.

### Can Saccharomyces cerevisiae CBC 1234 be used as an adjunct for C. difficile colitis?

Saccharomyces cerevisiae CBC 1234 may serve as an adjunctive therapy for C. difficile colitis, though it should never replace standard antibiotic treatment with vancomycin or fidaxomicin. The probiotic may support gut recovery and reduce recurrence risk when used alongside primary medical therapy, but clinical evidence specific to this strain for C. difficile is limited. Always consult a healthcare provider before using probiotics in active C. difficile infection, as individual risk factors may affect suitability.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*